Created at 2:36 p.m. Jun, 21, 2024
Author: mohannadkh10
Co-authors: DillingerMed
Related Note: 1504363340097 3
Rationale for change

Both amboss (link) and UW (table) 2641
Name rasburicase for both prophylaxis and treatment while rasburicase alone for treatment

Amboss text
Indications
Treatment of established TLS
Prophylaxis for intermediate to high-risk patients (low to intermediate risk we use allopurinol)
Source: AMBOSS - https://next.amboss.com/us/article/uJ0pDS?q=tumor%20lysis%20syndrome#-X1D0f0

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step2_v12::#SketchyIM::07_Rheumatology::02_Crystalline_Disorders::01_Gout_&_Pseudogout_SOAP #AK_Step1_v12::#Pixorize::01_Biochemistry::02_Biochemical_Pathways::08_Purine_Excretion #AK_Step1_v12::#SketchyBiochem::03_Molecular_Biology::01_DNA::06_Purine_Salvage_Pathway #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::34_Tumor_lysis_syndrome #AK_Step1_v12::#NBME::20 #AK_Step2_v12::#AMBOSS::U30b3f #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step2_v12::#NBME::Form12 #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::03_Anti-inflammatory::02_Gout_drugs #AK_Step1_v12::#Bootcamp::Musculoskeletal::02_Non-Rheumatologic_Disease::02_Gout #AK_Step2_v12::#NBME::Form16::Section_1 #PANCE::HEME::neoplasms_premalignancies_malignancies #AK_Step1_v12::#OME::PreClinical::Biochemistry #AK_Step1_v12::#Physeo::09_Pharm::09_Musculoskeletal::08_Acute_and_Chronic_Gout_Treatment #AK_Step2_v12::#B&B::09_MSK::01_General::03_Gout::Extra #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Other::Only_Step_1&2_Overlap #AK_Step2_v12::#NBME::Form14::Section_4 #AK_Step1_v12::#FirstAid::05_Pharm::03_Toxicities_and_Adverse_Effects::08_Drug_reactions-musculoskeletal/skin/connective_tissue #AK_Step2_v12::#UWorld::Step::107069 #AK_Step1_v12::#Pixorize::03_Pharmacology::13_Musculoskeletal_Pharm::13_Allopurinol/Febuxostat #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::16_Acute_Leukemia #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#Physeo::05_Biochem::05_Metabolism::18_Purines_&_Pyrimidines #AK_Step1_v12::#FirstAid::11_Musculoskeletal_Skin_and_Connective_Tissue::04_Pharm::09_Gout_drugs #AK_Step1_v12::#AMBOSS::C-0qzi #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::05_Tumor_Lysis_Syndrome #AK_Step2_v12::#FirstAid::12_Pediatrics::11_Pediatric_Oncology::01_Leukemia #AK_Step1_v12::#B&B::13_Immunology::05_Inflammatory_Disorders::02_Gout_Drugs::Extra #AK_Step1_v12::#FirstAid::11_Musculoskeletal_Skin_and_Connective_Tissue::04_Pharm::09_Gout_drugs::01_Chronic_gout_drugs_(preventive)::*Allopurinol_Febuxostat #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::12_Lymphoma #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::01_Acute_Leukemias_SOAP #AK_Step1_v12::#AMBOSS::WXaPCQ #PANCE::EOR::IM #AK_Step2_v12::#SketchyIM::04_Nephrology_&_Urology::05_Retired_Lessons::01_AKI_SOAP_[OLD_VERSION]